GlassScriptPhysician profile
Mark O Mccorkindale
NPI 1679528616
$3,921.46
in general payments reported to CMS, 2019-2025
40 companies · $638 in 2025
The $638 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123 · 2020: $396 · 2021: $862 · 2022: $721 · 2023: $554 · 2024: $627 · 2025: $638.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,819.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,819.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $899.92 | 2019-2025 | Evenity, Prolia, Repatha |
| Abbvie INC. | $609.55 | 2021-2025 | |
| Novo Nordisk INC | $456.05 | 2020-2025 | Ozempic, Rybelsus |
| Astellas Pharma US INC | $187.21 | 2023-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $182.36 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $161.66 | 2020-2024 | Leqvio |
| Pfizer INC. | $118.61 | 2019-2025 | |
| Lilly USA, LLC | $101.42 | 2021-2024 | Mounjaro |
| Merck Sharp & Dohme LLC | $97.24 | 2020-2023 | Vaxelis, Vaxneuvance, Gardasil 9 |
| E.R. Squibb & Sons, L.L.C. | $88.11 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $86.60 | 2022-2025 | |
| Daiichi Sankyo INC. | $84.91 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $66.61 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $61.65 | 2022-2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $60.73 | 2019-2025 | Trintellix |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Mccorkindale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.